BRAF and Hypertension: In conclusion, we have established a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables: initial radical treatment, the number of cycles of first- and second-line chemotherapy, BRAF gene mutation status, and presence of hypertension.